The FISH (Fluorescence In Situ Hybridization) - Eosinophilic Leukemia Panel Test is a specialized diagnostic tool used to identify specific genetic abnormalities associated with eosinophilic leukemia, a rare form of leukemia characterized by the overproduction of eosinophils, a type of white blood cell. This test is particularly valuable for the precise diagnosis and management of the disease, enabling healthcare providers to tailor treatment plans more effectively.
Conducted at DNA Labs UAE, a leading facility in genetic testing and analysis, the test employs the FISH technique to detect chromosomal anomalies at a molecular level. By applying fluorescent probes that bind to specific DNA sequences on chromosomes, it highlights the genetic alterations that are hallmarks of eosinophilic leukemia, such as translocations or deletions.
Priced at 2950 AED, the FISH - Eosinophilic Leukemia Panel Test represents a critical step forward in the personalized medicine approach, offering patients a targeted diagnosis that can significantly influence their treatment outcomes. The cost reflects the sophisticated technology and expertise required to perform this advanced genetic analysis.
The 1p and 19q test is a specialized genetic test conducted to detect the deletion of parts of chromosomes 1 and 19, a condition often found in certain types of brain tumors, such as oligodendrogliomas. This test is crucial for the diagnosis, prognosis, and treatment planning for patients with these tumors, as tumors with these deletions tend to respond better to chemotherapy and radiation, and patients generally have a better overall prognosis.
At DNA Labs UAE, this test is offered for 2,930 AED. The lab utilizes advanced genetic testing techniques to accurately identify the presence or absence of these chromosomal deletions. The process involves collecting a sample of the tumor tissue, which is then analyzed using sophisticated molecular biology methods to detect the chromosomal abnormalities. Results from the 1p and 19q test can significantly influence the management and therapeutic approach for patients with brain tumors, making it a valuable tool in the field of neuro-oncology.
A Biopsy Electron Microscopy Test is a highly specialized diagnostic procedure performed at DNA Labs UAE, designed to examine tissue samples at an ultrastructural level. This test employs electron microscopy, a powerful tool that uses a beam of electrons to create images of the specimen, allowing for the visualization of structures at a much higher resolution than traditional light microscopy. This detailed view can reveal cellular and subcellular components, making it invaluable in diagnosing a wide range of diseases, including various types of cancer, infectious diseases, and genetic conditions.
The process involves taking a small sample of tissue from the patient, which is then prepared through a series of steps to make it suitable for examination under the electron microscope. This preparation includes fixation, dehydration, embedding, sectioning, and staining of the tissue sample to enhance contrast.
At DNA Labs UAE, the cost of a Biopsy Electron Microscopy Test is set at 2400 AED. This investment covers the intricate process of sample preparation, the use of advanced electron microscopy technology, and the expertise of specialized professionals who interpret the ultrastructural details to provide a precise diagnosis. Given its detailed nature, this test is particularly useful when other diagnostic methods do not provide sufficient information or when an ultrastructural analysis is deemed necessary to reach a conclusive diagnosis.
Chronic Neutrophilic Leukemia (CNL) is a rare type of cancer that affects the white blood cells, specifically the neutrophils, leading to their abnormal increase. The condition is often associated with mutations in certain genes, most notably the CSF3R gene, particularly in exons 14 and 17, and the SETBP1 gene in exon 4. These genetic mutations play a crucial role in the development and progression of CNL, making their identification vital for accurate diagnosis and targeted treatment strategies.
DNA Labs UAE offers a specialized genetic test designed to detect mutations in the CSF3R gene (exons 14 and 17) and the SETBP1 gene (exon 4), which are critical in the diagnosis of Chronic Neutrophilic Leukemia. This test is an essential tool for healthcare providers in confirming the presence of CNL, enabling the development of a personalized treatment plan based on the genetic makeup of the individual's leukemia.
The test is priced at 2400 AED, reflecting the advanced technology and expertise required to accurately identify these specific genetic mutations. Conducted in a state-of-the-art facility, DNA Labs UAE ensures that patients receive reliable and timely results, aiding in the effective management of Chronic Neutrophilic Leukemia.
The "cKIT Mutation Screening Exons 9, 11, 13, 17 Gastrointestinal Stromal Tumors Test" is a specialized diagnostic procedure available at DNA Labs UAE, designed to detect mutations in specific exons (9, 11, 13, and 17) of the cKIT gene. These mutations are critically important in the context of gastrointestinal stromal tumors (GISTs), as they can influence both the prognosis and the therapeutic approach for patients. GISTs are a type of tumor that occurs in the digestive tract, and the presence of cKIT mutations can make them responsive to targeted therapies, improving patient outcomes.
The test involves collecting a tissue sample from the tumor, which is then analyzed using advanced molecular techniques to identify any genetic alterations in the specified exons of the cKIT gene. This precision approach allows for a more tailored treatment plan, which could include targeted therapies specifically designed to address the identified mutations.
Offered at a cost of 2400 AED, this test represents a critical step for patients diagnosed with GIST, providing them with essential information that can guide their treatment plan. DNA Labs UAE is equipped with state-of-the-art facilities and employs highly skilled professionals to ensure accurate and reliable test results, contributing to better management and outcomes for GIST patients.
Hemochromatosis is a genetic disorder characterized by excessive absorption of iron by the body, leading to its accumulation in various organs, potentially causing severe health issues such as liver disease, heart problems, and diabetes. The disorder is primarily linked to mutations in the HFE gene, notably the H63D, S65C, and C282Y mutations. These mutations disrupt the normal regulation of iron absorption, leading to the accumulation of iron.
The Hemochromatosis Common Mutation Analysis in HFE Gene H63D, S65C, and C282Y Test is a genetic test aimed at identifying these specific mutations within the HFE gene. Conducted by DNA Labs UAE, this test plays a crucial role in diagnosing hereditary hemochromatosis, enabling early detection and management of the condition to prevent its severe consequences.
Priced at 2400 AED, the test offers a comprehensive analysis, providing essential genetic information that can guide both patients and healthcare providers in making informed decisions about treatment and management strategies, including dietary adjustments, phlebotomy, or chelation therapy, depending on the severity of iron overload and the presence of symptoms. This test is a valuable tool in the proactive management of hereditary hemochromatosis, offering a pathway towards improved health outcomes for individuals carrying these genetic mutations.
The "Hemophilia A Common Mutation Screening Factor VIII Intron 22 Inversion Analysis Test" is a specialized diagnostic procedure offered by DNA Labs UAE, designed to identify the most prevalent genetic mutation associated with Hemophilia A. This condition, a bleeding disorder caused by a deficiency of clotting Factor VIII, often results from a specific inversion mutation within intron 22 of the Factor VIII gene. The test is crucial for accurate diagnosis, enabling targeted treatment and management strategies for affected individuals. Priced at 2400 AED, this test represents a vital tool in the genetic analysis of Hemophilia A, providing essential information for patients, their families, and healthcare providers on the underlying genetic cause of the disorder. Through a detailed examination of the patient's DNA, this test can effectively confirm the presence of the inversion mutation, guiding decisions on prophylactic treatments and potentially improving the quality of life for those with Hemophilia A.
The "Her-2 Neu Ca Breast Test" is a diagnostic procedure conducted to evaluate the presence of the HER2 protein in breast cancer cells. HER2 (Human Epidermal Growth Factor Receptor 2) is a gene that can play a role in the development of breast cancer. Its overexpression or amplification in breast cancer cells can influence the behavior of the cancer, including its growth and spread. Testing for HER2 status is crucial as it helps in determining the most effective treatment options for patients. Treatments that specifically target HER2-positive breast cancers are available and can significantly improve outcomes for patients with this type of cancer.
The test is performed on a sample of breast cancer tissue, usually obtained through a biopsy or surgery. It involves specialized techniques to measure the amount of HER2 protein or the number of HER2 genes in the cancer cells. The results of the HER-2 Neu Ca Breast Test can classify breast cancer as HER2-positive or HER2-negative, guiding oncologists in tailoring treatment plans that are more personalized and potentially more effective.
In the United Arab Emirates, the HER-2 Neu Ca Breast Test is available at DNA Labs UAE, a leading diagnostic facility known for its advanced testing capabilities and commitment to patient care. The cost of the test at DNA Labs UAE is 2400 AED, reflecting the intricate processes and specialized technology required to accurately assess HER2 status. Patients opting for this test at DNA Labs UAE can expect reliable results that are critical for making informed decisions about their breast cancer treatment options.
The IDH1 and IDH2 Mutation Analysis Test is a sophisticated diagnostic procedure aimed at detecting mutations in the IDH1 and IDH2 genes, which are crucial indicators in the assessment and management of certain types of cancers, including gliomas, acute myeloid leukemia (AML), and chondrosarcoma. These mutations can influence the prognosis and therapeutic approach for patients, making the test a valuable tool in personalized medicine.
Performed at DNA Labs UAE, a facility renowned for its state-of-the-art technology and expert analysis, the test involves examining the patient's DNA sample to identify any alterations in the IDH1 and IDH2 genes. The results can help guide oncologists in deciding the most effective treatment strategy, potentially including targeted therapies that specifically address the mutated genes.
The cost of the IDH1 and IDH2 Mutation Analysis Test at DNA Labs UAE is set at 2400 AED. This investment covers the comprehensive analysis necessary to ensure accurate and reliable results, providing critical insights into the patient's genetic profile and how it may impact their cancer treatment and prognosis.
The Methylenetetrahydrofolate Reductase (MTHFR), Factor V (F5), and Factor II (F2) test is a comprehensive genetic assessment conducted at DNA Labs UAE. Priced at 2400 AED, this test is designed to identify mutations in the MTHFR gene and to screen for genetic variations in the Factor V and Factor II genes, which are crucial for understanding an individual's risk of developing blood clot disorders and certain types of cardiovascular diseases.
The MTHFR gene plays a significant role in processing amino acids, which are the building blocks of proteins. A mutation in this gene can lead to elevated levels of homocysteine in the blood, a risk factor for heart disease, stroke, and other health issues. The Factor V Leiden mutation (related to the F5 gene) and the prothrombin G20210A mutation (related to the F2 gene) are both linked to an increased risk of developing harmful blood clots. Identifying these genetic variations can help in the early detection and management of associated health risks.
Performed at the state-of-the-art facilities of DNA Labs UAE, this test involves a simple blood draw. The results not only provide valuable insights into an individual's genetic predisposition to certain conditions but also assist healthcare providers in developing personalized treatment and prevention strategies.
